Table 2.
Outcome measures: Non-invasive tests.
| Standard Clinical Care (n = 8) | Exercise (n = 12) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Post | Within Group p-Value | Baseline | Post | Within Group p-Value | Between Group p-Value |
|
| Clinical Decision Aids | |||||||
| NFS, Median (IQR) | −1.75 (2.74) | −1.42 (2.60) | 0.653 | −1.51 (1.25) | −1.69 (1.30) | 0.679 | 0.431 |
| FIB-4 | 1.07 (0.48, 2.40) | 1.02 (0.47, 2.20) | 0.671 | 1.15 (0.85, 1.57) | 1.03 (0.76, 1.40) | 0.077 | 0.777 |
| Serum Biomarkers | |||||||
| Adiponectin, ng/mL | 3271 (2210, 4843) | 3141 (2101, 4698) | 0.468 | 3448 (2947, 4035) | 3530 (3060, 4071) | 0.652 | 0.440 |
| CK18, IU/L | 85.7 (31.1, 236.4) | 85.8 (16.1, 458.1) | 0.998 | 231.5 (76.3, 702.1) | 177.0 (56.7, 552.6) | 0.034 | 0.062 |
| FGF21, ng/mL | 372 (247, 562) | 390 (190, 802) | 0.670 | 521 (346, 783) | 277 (153, 501) | 0.044 | 0.037 |
| FGF21/Adiponectin | 0.11 (0.06, 0.19) | 0.13 (0.07, 0.27) | 0.602 | 0.15 (0.09, 0.24) | 0.07 (0.04, 0.15) | 0.049 | 0.099 |
| PAI-1, ng/mL | 206 (120, 353) | 279 (187, 415) | 0.061 | 166 (124, 221) | 130 (101, 168) | 0.160 | 0.020 |
| ≥17 IU/L reduction in ALT, n (%) | 1 (13) | 7 (58) | <0.001 | ||||
| Imaging biomarkers | |||||||
| MRI-PDFF liver fat, % | 19.0 (11.8, 30.6) | 18.8 (10.2, 34.7) | 0.934 | 19.0 (11.8, 30.6) | 18.8 (10.2, 34.7) | 0.018 | 0.011 |
| ≥30% relative reduction in MRI-PDFF, n (%) | 1 (13) | 4 (33) | 0.008 | ||||
ALT = alanine aminotransferase; CK = cytokeratin; FGF = fibroblast growth factor, FIB-4 = fibrosis-4 index; MRI = magnetic resonance imaging; NAFLD = nonalcoholic fatty liver disease; NFS = NAFLD Fibrosis Score; PAI = plasminogen activator inhibitor, PDFF = proton density fat fraction. Reported as geometric mean (95% CI) unless indicated.